ACHL Logo
ACHL
Achilles Therapeutics Plc - ADR
$1.36
0.00%
Company Details
Name

Achilles Therapeutics Plc

Website

https://www.achillestx.com/

Sector

Manufacturing

Industry

Biological Product (except Diagnostic) Manufacturing

Categories

CEO

-

Employees

237

Description

achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.

Stock Quote
Market Cap

$55.46M

52 Week High

$1.43

PE Ratio

-

52 Week Low

$0.74

EPS

-

Shares Outstanding

40.78M

Dividend Yield

-

Dividend Per Share

-

Company Details
Name

Achilles Therapeutics Plc

Website

https://www.achillestx.com/

Sector

Manufacturing

Industry

Biological Product (except Diagnostic) Manufacturing

Categories

CEO

-

Employees

237

Description

achilles therapeutics’ mission is to develop next-generation, patient-specific therapies that harness the immune system to destroy cancer cells. the therapies will target truncal (also known as clonal) tumour neo-antigens, unique flags to the immune system present on the surface of every cancer cell. these truncal neo-antigens are created early in the cancer’s evolution and present on all cancer cells in an individual patient’s tumour but not on healthy cells, so could allow scientists to target and destroy tumours without harming healthy tissues. achilles therapeutics brings together four scientific founders with world leading expertise in the understanding of cancer evolution, bioinformatics and the development of immunotherapies.

Latest News
Related Stocks